Industry / Czech Republic
Zentiva Expands Eastwards
October 2007 | Industry NewsCzech drugmaker Zentiva recorded a disappointing performance on its home market in H107 with sales receding 5.6% to CZK2,226mn (US$115.08mn). Chief Financial Officer Petr Sulc blames recent drug market reforms, which have impacted volume sales.
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Emerging Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Emerging Europe Pharma & Healthcare Insight please click on the trial link below.
